Neurophet

Neurophet AAQS

The The AAQS of Neurophet (380550.KQ) as of Oct 20, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).

AAQS

3

YoY

0.00%

Last updated:

Neurophet has a current AAQS of 3.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Neurophet in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Neurophet AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2022
3.00 KRW
Jan 1, 2023
3.00 KRW
Jan 1, 2024
3.00 KRW
Jan 1, 2025
3.00 KRW
The Neurophet AAQS history
YEARAAQSYoY
30.00%
30.00%
30.00%
3—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurophet Stock analysis

What does Neurophet do? Neurophet Inc is a South Korean company operating in the Health Care sector, headquartered in Seoul. The company has 135 employees and is listed on the Korean stock exchange with the ticker 380550.KQ and ISIN KR7380550004. Neurophet Inc went public on July 25, 2025, marking its initial public offering. The company focuses on the research, development, and sales of brain imaging analysis software, including PET image quantitative analysis software called 'Neurophet SCALE PET' and neurodegenerative brain disease diagnosis support software named 'Neurophet AQUA'. Additionally, Neurophet Inc develops and sells therapeutic medical devices and provides medical artificial intelligence solutions. The company's website is https://www.neurophet.com/. Neurophet Inc operates within the Health Care Technology industry, specializing in software and AI-driven tools for medical imaging and diagnostics. The company's products are designed to support healthcare professionals in analyzing brain imaging data and diagnosing neurological conditions. As a technology-focused health care provider, Neurophet Inc aims to enhance diagnostic accuracy and efficiency through its software solutions. The company's operations are based in Seoul, South Korea, and it is engaged in both the development and commercialization of its medical technology products. Neurophet Inc's business model centers on creating innovative software tools that address specific challenges in neurology and brain imaging analysis. Neurophet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurophet stock

The AAQS of Neurophet is 3 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Neurophet since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Neurophet

All Key Metrics — Neurophet